The effect of the proteasome inhibition of the antiproliferative effect of anthracycline antibiotics.

Charles University in Prague Faculty of Pharmacy in Hradec Králové Department of Biochemical Sciences Candidate: Jana Kroupová Supervisor: PharmDr. Anna Jirkovská, Ph.D. Title of diploma thesis: The effect of the proteasome inhibition of the antiproliferative effect of anthracycline antibiotics Anthracycline antibiotics (daunorubicin, doxorubicin) belong to the most effective antitumor drugs. In current clinical practice they are used mostly in the combinations with either "classical" or new targeted antitumor drugs. The proteasome inhibitors (bortezomib and carfilzomib) are also viewed as a part of new "targeted" antitumor drugs. The proteasome is a multienzyme complex in eukaryotic cells which is responsible for intracellular degradation of proteins. The proteasome inhibitors have been largely used in the therapy of multiple myeloma, but their potential has been also studied in the case of other malignancies. Their use in the combination with anthracyclines could be a possible alternative in the therapy of some tumor illnesses, but the effect of combination of anthracyclines and proteasome inhibitors on tumor cells have not been sufficiently explained. The anthracycline therapy is also accompanied by serious adverse side effect - the cardiotoxicity, which potential could be influenced by the..